SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (952)	12/29/1998 11:09:00 PM
From: ubrx	Read Replies (2) of 1477

Miljenko, Interesting article. Thanks for the post. The only mention of the phase II trials for Fiblast in PVD is in the last annual report: "With Wyeth-Ayerst, Scios is conducting Phase II clinical studies in patients with critical limb ischemia and intermittent claudication, the most prevalent form of PVD. These trials follow successful studies by Scios' academic collaborators showing both revascularization and restored muscle function in PVD models. Scios and Wyeth-Ayerst are also studying the use of Fiblast as a “biological bypass” for the treatment of coronary artery disease (CAD)." I saw no mention of a phase II trial for CAD. Is there a human phase II trial ongoing? I couldn't find any recent updates or press releases on the Scios website. It is about time for some news. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next